Blog

Amol Akhade: Does CTRT improve outcomes in gall bladder cancer?

Amol Akhade/hiranandanihospital.org

Jan 23, 2025, 14:32

Amol Akhade: Does CTRT improve outcomes in gall bladder cancer?

Amol Akhade, Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics, shared the following on X:

“Adjuvant chemo vs. chemo followed by CTRT in gall bladder cancer. Phase 3 RCT from India. Accelerate trial with 94 patients. Post-RO resection: 49 got chemo, 45 got chemo followed by CTRT. Median OS NR vs. 34.56 months. Median RFS 51.96 vs. 43.99 months.

So, the addition of CTRT to chemo alone does not improve outcomes in resected gall bladder cancer. What are your thoughts on this? A small trial, affected by the COVID pandemic, but probably with the right conclusion.”

Accelerate trial adjuvant chemotherapy Amol Akhade cancer Cancer research cancer treatment clinical trials CTRT gall bladder cancer India OncoDaily Oncology Phase 3 Trial survival outcomes

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers